Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection

Bunyamin Dikici1, Abdullah Dagli, Hasan Ucmak

  • 1Department of Pediatrics, Abant Izzet Baysal University, Duzce Medical Faculty, Duzce, Turkey. bdikici@hotmail.com

Insights

This study found vitamin E did not improve liver enzymes or viral load in children with chronic hepatitis B virus (CHB) infection. Further research into other immunomodulators is recommended for this patient group.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Immunology

Background:

  • Chronic hepatitis B virus (CHB) infection affects children worldwide.
  • The immunotolerant phase is characterized by high viral replication and normal liver enzymes.
  • Effective treatment strategies for this phase are limited.

Purpose of the Study:

  • To investigate the efficacy of vitamin E in children with immunotolerant-phase CHB infection.
  • To evaluate the impact of vitamin E on serological, virologic, and biochemical markers.
  • To determine if vitamin E offers a beneficial effect in this pediatric population.

Main Methods:

  • A prospective, randomized study involving 58 children with immunotolerant CHB.
  • Group 1 received vitamin E (100 mg/day) for 3 months; Group 2 (control) received no medication.
  • Outcomes assessed included alanine transaminase (ALT) levels and hepatitis B virus (HBV)-DNA load at baseline, 3 months, and 6 months post-therapy.

Main Results:

  • No significant changes in mean ALT values or HBV-DNA load were observed in the vitamin E group compared to the control group.
  • No statistically significant differences in ALT or HBV-DNA levels were found between the two groups at any time point.
  • Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) clearance or seroconversion were not observed in either group.

Conclusions:

  • Vitamin E demonstrated no beneficial effect in children with immunotolerant CHB infection.
  • This is the first study to investigate vitamin E's efficacy in this specific pediatric CHB phase.
  • Future research should explore alternative immunomodulatory protocols for treating immunotolerant CHB in children.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...